Darmiyan Receives FDA Approval for BrainSee, the First Prognostic Test for Predicting Likelihood of Progression to Alzheimer's Dementia

FDA's De Novo approval of BrainSee represents a major advancement in Alzheimer's diagnostics. Utilizing cutting-edge image processing and medical AI, BrainSee establishes a new standard for predicting progression from amnestic mild cognitive impairment (aM... Diagnostics, Neurology, FDA Darmiyan, BrainSee, Alzheimer's
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news